Nureca IPO To Open Next Week. Here Are Things To Know
Nureca's Rs 100 crore will open for subscription on February 15, 2021. The shares of Nureca, which owns the Dr Trust brand, will be sold in the price band of Rs 396-400 apiece. The public offer will close on February 17, 2021. The shares are likely to be listed on BSE and NSE.
Investors can bid for a minimum one lot of 35 equity shares and in multiples thereafter, up to 14 lots. A total of up to 75 per cent of the issue will be reserved for qualified institutional buyers (QIB), up to 10 per cent for retail investors and remaining 15 per cent for the non-institutional category. Shares worth Rs 50 lakh will be reserved for eligible employees and these will be offered at a discount of Rs 20 per share.
The proceeds of the issue will be used for funding the company's incremental working capital requirements and for general corporate purposes.
ITI Capital Ltd is the sole book running lead manager and Link Intime India Private is the registrar to the issue.
Nureca is engaged in the business of home healthcare and wellness products. It sells its products through its own website as well as online channel partners such as e-commerce players, distributors and retailers.
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.
